Status:
UNKNOWN
Shark Mouth Modified Pancreaticojejunostomy
Lead Sponsor:
Peking University Third Hospital
Conditions:
Pancreatic Cancer
Periampullary Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
Pancreaticoduodenectomy (PD) is one of the most complicated surgical procedure and one of the standard treatments for benign and malignant disease of pancreatic head and periampullary region. Improvem...
Detailed Description
A pancreaticoduodenectomy (PD) still remains the curable treatment choice for most of malignant and benign neoplasms of the head of the pancreas and periampullary region. Though the safety of PD has b...
Eligibility Criteria
Inclusion
- Patients diagnosed with pancreatic cancer or other diseases which need pancreaticoduodenectomy
- Operation-tolerated
- Informed consent
Exclusion
- History of abdominal operation
- Pancreaticoduodenectomy is given up during operation
- Patients require to exit from the study anytime
- Pregnancy
Key Trial Info
Start Date :
December 8 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03366038
Start Date
December 8 2017
End Date
May 1 2020
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of General Surgery, Peking University Third Hospital
Beijing, China, 100191